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OBJECTIVES:This study compares socio-demographic characteristics, comorbidity
profiles, and functional impairments affecting adults diagnosed with attention
deficit hyperactive disorder (ADHD) to their non-ADHD counterparts in Europe.
METHODS: Data are from the 2011 National Health and Wellness Survey (NHWS),
conducted annually by Kantar Health. The NHWS has been administered annually
since 2002 among samples of adults drawn from an international consumer panel
recruited and maintained by Lightspeed research. Data reported in this study were
gathered between September and December 2011 in Germany, UK, France, Spain,
and Italy. T-tests of means and proportions were used to test for significant differ-
ences between adults with diagnosed ADHD and a non-ADHD control group from
the NHWS sample. All differences reported below were significant at the p0.05
level. RESULTS: A total of 235 NHWS participants reported having received a diag-
nosis for ADHD from a physician. Diagnosed ADHD respondents were more fre-
quently male (59% vs. 49%) and less likely married (38% vs. 50%) than non-ADHD
controls. Diagnosed ADHD respondents were more likely to report sleep difficulties
(67% vs. 25%), anxiety (61% vs. 16%), depression (59% vs. 12%), or headaches (57% vs.
39%). Likelihoods of a general practitioner visit (77% vs. 65%), an emergency room
visit (34% vs. 11%), or a hospitalization (32% vs. 8%) within the past 6 months were
greater among diagnosed ADHD respondents than non-ADHD controls. Diagnosed
ADHD respondents were also less likely employed full-time (27% vs. 39%), and
more likely to report health-related work productivity loss (55% vs. 20%).
CONCLUSIONS: Adults from 5 western European nations with self-reported diag-
noses of ADHD reported higher rates of comorbidity with a variety of mental,
emotional, or physical disorders, higher rates of health resource utilization, lower
rates of full-time employment and higher rates of health-related work productivity
impairment than adults without ADHD.
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OBJECTIVES: To gain insights into the perceived value of alternative treatment
formulations in the management of schizophrenia. METHODS: A search of 75
health technology assessment (HTA) agencies was performed to identify single
technology appraisals published between January 2010 and June 2012 on pharma-
ceutical treatments for schizophrenia. Per agency, only the most recent appraisal
for each drug identified was selected for analysis. Reasons for recommendation
and non-recommendation were evaluated in-depth for each appraisal. RESULTS:
In total 32 appraisals (9 rejections; 23 recommendations) were identified across 12
agencies. These appraisals represent the most recent decision made for a specific
drug by a particular agency. Overall 5 different formulations were assessed includ-
ing long-acting depot formulations (14 appraisals), oral immediate release (IR) tab-
lets (13), orodispersible tablets (3), an oral long release (LR) tablet (1), and an oral
solution (1). Non-recommendations were only identified for depot, oral IR and oral
LR formulations. In most cases high drug costs, lack of head-to-head and long-term
clinical data were the main reasons for rejection. Submissions resulting in a rec-
ommendation were identified for all but the LR tablet formulation. Reasons for
recommendation included proven clinical non-inferiority to direct comparators,
cost savings and a better dosing schedule. As most new formulations did not offer
a benefit in efficacy, decisions were weighted on cost. In all long-acting formulation
submissions, manufacturers stated that use of the drug would lead to improved
patient compliance. Only one submission (HAS) provided data to support this
claim. SMC and AWMSG were the only agencies to criticise the absence of compli-
ance data. CONCLUSIONS: A higher drug price for a new formulation is only war-
ranted when clear clinical advantages are presented. This is particularly evident
for long-acting formulations where a higher price, on grounds of improved com-
pliance, is not favourable. There was very little disparity between agencies in their
decision making approach.
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OBJECTIVES: To put the apparent rise of the administrative prevalence of atten-
tion-deficit/hyperactivity disorder (ADHD) in the region of Nordbaden in South-
western Germany into context by analyzing the most frequently diagnosed mental
health problems in this population. METHODS: The complete claims database of
the organization of physicians registered with statutory health insurance [SHI]
(Kassenaerztliche Vereinigung, KV) in Nordbaden/Germany was available for analy-
sis, covering the total regional population enrolled in SHI (2.2 million). The data-
set for years 2003 to 2009 was reorganized as to allow patient-centered evaluation.
RESULTS:Most frequently diagnosed mental health problems in 2009 were depres-
sive episodes (ICD-10 code F32.9), with an overall administrative 12-months prev-
alence rate of 8.3%; unspecified somatoform disorders (F45.9), 4.8%; harmful use of
tobacco (F17.1), 3.4%; neurasthenia (F48.0), 2.3%; and adjustment disorders (F43.2),
2.2%. Uncomplicated hyperkinetic disorder (HKD, F90.0) was the number one rea-
son for contacts with health care providers in children (age group 6-12 years, 7.2%)
and adolescents (13-17 years, 3.7%), reported more than twice as often as the next
frequently diagnosed mental health problems, namely various developmental,
speech, and adjustment disorders. In preschoolers, speech and developmental
problems were diagnosed more frequently than HKD (1.0%). From 2003 to 2009, the
administrative prevalence of ADHD (HKD/F90.0 and hyperkinetic conduct disorder,
HKCD/F90.1, combined) increased by 79%, i.e., from 0.53% in 2003 to 0.95% (overall;
6-12 years, 8.0%; 13-17 years, 4.2%) in 2009. Notwithstanding lower absolute num-
bers, ADHD prevalence in adults increased more than fourfold, from 0.04% (2003) to
0.17% (2009). CONCLUSIONS: By 2009, ADHD represented the leading mental
health related cause of service utilization among children and adolescents in Nor-
dbaden. The present analysis underscores the need for in-depth research address-
ing the quality, cost, cost effectiveness, and broader economic implications of
health and social service provision for children, adolescents, and adults with a
diagnosis of ADHD.
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OBJECTIVES: To gain insight into the reimbursement landscape of pharmacologi-
cal treatments against alcohol dependency.METHODS:We have conducted a man-
ual search of 75 Health Technology Assessment (HTA) agencies’ websites for alco-
hol-related assessments published worldwide since 2001. All reports were
categorized by HTA type, scope and outcome. Using a standardized set of categor-
ical criteria, we investigated the recommendations for pharmacological treat-
ments of alcohol disorders to identify common patterns in key decision drivers in
this therapeutic area. RESULTS:We identified a total of 81 HTA reports dedicated to
treatment of alcohol-related disorders. By the time of this study, 70% of the HTA
reports were completed and therefore included into the analysis. The 57 published
reports comprised 13 Single Technology Assessments (STA), 1 Multiple Technology
Assessment (MTA), 6 Clinical Guidelines (CG), 14 Public Health Reviews, 6 Proce-
dure / Intervention Assessments and 17 Literature Reviews. While 40 HTAs were
mostly focused on public health impact of alcohol disorders and general organiza-
tion of treatment, pharmacological treatment of alcohol dependence was assessed
in 17 reports (within the scope of STAs, MTAs or CGs). Medications assessed the
most were acamprosate and naltrexone. The vast majority of agencies have issued
positive recommendations for these drugs, assuming they are used as second-line
options and/or in combination with psychosocial interventions. Naltrexone was
rejected by several agencies (e.g. AHTAPol, SIGN), partially justified by high risks/
major adverse events and poor data supporting the benefits of the drug.
CONCLUSIONS:Alcohol-related disorders attract attention of HTA agencies world-
wide. Current research however shows that only a limited number of reports assess
medications. One of the main decision drivers for approvals was the mere neces-
sity of a pharmacological treatment which emphasizes a high unmet need in the
management of alcohol dependence.
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OBJECTIVES: Research has been conducted on parent and patient preferences for
ADHD medication, yet medication attributes that may influence the physician’s
prescribing behavior are not well understood. The aim of this study was to identify
the primary attributes of ADHD medications that influence the prescribing behav-
ior of physicians treating ADHD, and to explore country variation in these factors
across Europe.METHODS:A retrospective chart review of ADHD patients aged 6-17
was conducted in six European countries. Charts of 779 patients diagnosed be-
tween 2004-2007 were reviewed by 361 physicians. Physicians were asked to select
three main medication attributes influencing their selection of ADHD medication
for newly treated patients. The 19 total attributes were grouped by the researchers
into 6 domains: efficacy, duration of action (DOA), convenient dosing, prior expe-
rience, safety, and cost/other. Descriptive statistics were used to compare prescrib-
ing behavior by medication attributes, and chi-square tests assessed country
differences. RESULTS: Efficacy (33%), convenience (19.6%) and DOA (17.3%) were
the 3 most frequently selected attributes that influenced ADHD medication selec-
tion, followed by prior experience (13.3%), safety (11.4%) and cost/other (5.3%). DOA
was particularly important in France (23.0%) relative to its importance in the Neth-
erlands (13.9%), while convenient dosing was equally important across all coun-
tries except Italy (11.6%). Medication cost was significantly more important in the
Netherlands (13.9%) and Spain (8.0%) relative to France and the UK (1.6% and 2.3%,
respectively; p0.0001); while safety was rated highest among physicians in Italy
(22.7%) relative to those in the Netherlands (4.8%; p0.0001). CONCLUSIONS: Effi-
cacy, convenience, and duration were the most frequently selected medication attributes
influencing physician prescribing behavior; but there were differences in selected attri-
butes by country. Further research is needed to better understand the environmental
context influencing physician prescription behavior, and the impact that market-level
factors may have on treatment choices and patient outcomes in Europe.
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